EN PT


0909/2011 - Judicialization of access to treatment of rare genetic diseases: the Fabry Disease in the state of Rio Grande do Sul, Brazil
Judicialização do acesso ao tratamento de doenças genéticas raras: a Doença de Fabry no Rio Grande do Sul, Brasil

Author:

• Dailor Sartori Junior - Sartori Jr, D. - Porto Alegre, RS - Universidade Federal do Rio Grande do Sul (UFRGS) - <dailorjunior@gmail.com>

Co-author(s):

• Paulo Gilberto Cogo Leivas - Leivas, P.G.C. - Programa de Mestrado Acadêmico em Direito (UNIRITTER) - <pgleivas@uol.com.br>
• Ida V. D. Schwartz - Schwartz, I.V.D. - Serviço de Genética Médica do Hospital de Clínicas de Porto Alegre, Programa de Pós-Graduação em Ciências Médicas (UFRGS) - <ischwartz@hcpa.ufrgs.br>
• Giacomo Balbinotto Neto - Balbinotto Neto, G. - Programa de Pós-Graduação em Economia (UFRGS), Instituto de Avaliação de Tecnologia em Saúde (UFRGS) - <giacomo.balbinotto@ufrgs.br>
• Monica Vinhas de Souza - Vinhas de Souza,M - Porto Alegre, RS - Programa de Pós Graduação em Ciências Médicas (UFRGS) - <vsmonica@uol.com.br>
• Bárbara Corrêa Krug - Krug, B.C. - Programa de Pós-Graduação em Ciências Médicas (UFRGS) - <krug.barbara@gmail.com>
• Paulo D. Picon - Picon, P.D. - Programa de Pós Graduação em Ciências Médicas (UFRGS) - <paulopicon@gmail.com>

Thematic Area:

Assistência Farmacêutica

Abstract:

The judicialization of access to high-cost drugs for rare genetic diseases, such as Fabry Disease (alpha-galactosidase A deficiency), is a growing phenomenon and is little studied systematically. An observational, cross-sectional and retrospective study was conducted to characterize the lawsuits related to access to treatment of Fabry Disease by Enzyme Replacement Therapy in the State of Rio Grande do Sul until 2007. The study identified 13 lawsuits and 17 plaintiffs, 11 requested alfa and 6 betagalsidase. The State of RS, the Federal Government, and 5 municipalities figured as defendants, in the joinder of parties or not. There were 13 requests of preliminary injunction in which 12 were granted, and 2 sentences, both favorable. “Death risk” was claimed by doctors in 4 prescriptions and by lawyers in the 13 lawsuits. The data suggest the absence of discussions combining aspects of medical efficacy and safety, cost-effectiveness, economic impact, and legal and constitutional arguments, which requires a specific policy for rare genetic diseases to standardize access to treatment.

Keywords:

Fabry Disease Judicial Power Pharmaceutical Services

Content:

Access Issue in Scielo

Other languages:







How to

Cite

Sartori Jr, D., Leivas, P.G.C., Schwartz, I.V.D., Balbinotto Neto, G., Vinhas de Souza,M, Krug, B.C., Picon, P.D.. Judicialization of access to treatment of rare genetic diseases: the Fabry Disease in the state of Rio Grande do Sul, Brazil. Cien Saude Colet [periódico na internet] (2011/Jul). [Citado em 27/09/2024]. Está disponível em: http://cienciaesaudecoletiva.com.br/en/articles/judicialization-of-access-to-treatment-of-rare-genetic-diseases-the-fabry-disease-in-the-state-of-rio-grande-do-sul-brazil/7872?id=7872



Execution



Sponsors